Saxonov Serge 4
4 · 10x Genomics, Inc. · Filed Mar 25, 2026
Research Summary
AI-generated summary of this filing
10x Genomics (TXG) CEO Serge Saxonov Sells 15,000 Shares
What Happened
Serge Saxonov, CEO of 10x Genomics (TXG), sold a total of 15,000 shares in open-market transactions: 10,000 shares on March 23, 2026 at a weighted-average price of $19.13 (proceeds ~$191,297) and 5,000 shares on March 24, 2026 at a weighted-average price of $19.52 (proceeds ~$97,612). Total proceeds from these sales were roughly $288,909. These were sales (not purchases); sales are often routine and do not by themselves indicate a change in the insider’s view of the company.
Key Details
- Transaction dates and prices:
- Mar 23, 2026 — 10,000 shares, Wtd. avg price $19.13 (reported range $18.78–$19.41 per footnote).
- Mar 24, 2026 — 5,000 shares, Wtd. avg price $19.52 (reported range $19.49–$19.59 per footnote).
- Total shares sold: 15,000; total proceeds ≈ $288,909.
- Shares owned after transaction: Not specified in this Form 4 filing.
- Notable footnotes:
- Trades were effected under a Rule 10b5-1 trading plan adopted Nov 29, 2025 (F1) — prearranged plan.
- Filing discloses multiple trust relationships and prior transfers (e.g., transfers to Sirius Trust and Y/S Pot Trust on Mar 3, 2026; several 2018 irrevocable trusts hold 250,000 shares each of which the reporting person is trustee) (F3, F9, F10, F11).
- Weighted-average prices reflect multiple trades; the filer offers to provide per-trade breakdown to the SEC or issuer upon request (F2, F4).
- Timeliness: Report filed Mar 25, 2026 for transactions on Mar 23–24 — appears timely (no late filing flag).
Context
- These sales were executed under a 10b5-1 plan, which typically means trades were pre-scheduled and may not reflect contemporaneous insider views.
- For retail investors: purchases by insiders tend to be more informative than routine, pre-planned sales; treat this filing as a disclosure of liquidity by the insider rather than a directional signal.
Insider Transaction Report
Form 4
Saxonov Serge
DirectorChief Executive Officer
Transactions
- Sale
Class A Common Stock
[F1][F2][F3]2026-03-23$19.13/sh−10,000$191,297→ 1,177,273 total - Sale
Class A Common Stock
[F1][F4]2026-03-24$19.52/sh−5,000$97,612→ 1,172,273 total
Holdings
- 27(indirect: See footnote)
Class A Common Stock
[F5] - 213,250(indirect: See footnote)
Class A Common Stock
[F6] - 71,644(indirect: See footnote)
Class A Common Stock
[F3][F7] - 1,100,927
Class B Common Stock
[F8][F9]→ Class A Common Stock (1,100,927 underlying) - 180,938(indirect: See footnote)
Class B Common Stock
[F8][F9][F10]→ Class A Common Stock (180,938 underlying) - 1,750,000(indirect: See footnote)
Class B Common Stock
[F8][F11]→ Class A Common Stock (1,750,000 underlying)
Footnotes (11)
- [F1]The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on November 29, 2025.
- [F10]The shares are held by the Sirius Trust, for which the Reporting Person serves as trustee.
- [F11]250,000 shares are held by each of Polaris 2018 Irrevocable Trust, Antares 2018 Irrevocable Trust, Arcturus 2018 Irrevocable Trust, FLY 2018 Irrevocable Trust, LY 2018 Irrevocable Trust, MS 2018 Irrevocable Trust and NS 2018 Irrevocable Trust, of which the Reporting Person is the sole trustee.
- [F2]This transaction was executed in multiple trades at prices ranging from $18.78 to $19.41, inclusive. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
- [F3]Reflects the transfer by the Reporting Person of 13,644 shares of Class A Common Stock to the Y/S Pot Trust on March 3, 2026.
- [F4]This transaction was executed in multiple trades at prices ranging from $19.49 to $19.59, inclusive. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
- [F5]The shares are held by the Andromeda Trust, for which the Reporting Person serves as trustee.
- [F6]The shares are held by the Y/S Descendants' Trust, for which the Reporting Person serves as trustee.
- [F7]The shares are held by the Y/S Pot Trust, for which the Reporting Person serves as trustee.
- [F8]Each share of Class B Common Stock is convertible at any time at the option of the Reporting Person into one share of Class A Common Stock and has no expiration date. Additionally, each share of Class B Common Stock will convert automatically into one share of Class A Common Stock upon transfer, whether or not for value (subject to certain exceptions) and upon the occurrence of certain other events set forth in the Issuer's Amended and Restated Certificate of Incorporation.
- [F9]Reflects the transfer by the Reporting Person of 91,113 shares of Class B Common Stock to the Sirius Trust on March 3, 2026.
Signature
/s/ Randy Wu, as Attorney-in-Fact for Serge Saxonov|2026-03-25